CHE — Chemed Corp

Is CHE overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Care Facilities

Neutral As of October 3, 2026

Chemed Corp (CHE) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Medical Care Facilities) last closed at $507.50. The rating moved from Overbought to Neutral on September 30, 2026.

AI analysis

Chemed Corp (CHE) combines a defensive healthcare franchise (VITAS hospice) with a resilient home-services business (Roto-Rooter), producing stable cash flow and multiple secular tailwinds such as an aging population and steady household maintenance needs. Near-term catalysts include stable reimbursement outcomes, disciplined M&A and continued operational leverage, while primary headwinds are wage inflation, potential Medicare reimbursement changes and valuation sensitivity. Given current market risk-off sentiment, the company’s service-based revenue profile should offer relative resilience, though execution on cost control and regulatory cadence will determine performance across the next several quarters.

Key factors

  • Diversified service portfolio: Chemed Corp (CHE) operates both VITAS (hospice care) and Roto-Rooter (home services), providing revenue stability across healthcare and essential home repair demand.
  • Defensive cash flows: Recurring, service-based revenue streams and high-margin hospice operations produce predictable cash flow and resilience in risk-off market environments.
  • Favorable secular drivers: Aging population and growing hospice adoption support long-term demand for end-of-life care; steady household maintenance needs underpin Roto-Rooter service volumes.
  • Management track record and balance-sheet flexibility: Historically conservative capital allocation, ability to pursue tuck-in acquisitions and return capital to shareholders (share buybacks/dividends) support growth and valuation defense.
  • Limited direct exposure to drug-pricing policy: Chemed’s core businesses are service-oriented rather than drug-dependent, reducing near-term sensitivity to IRA-style drug price negotiations.
  • Near-term market tone supportive: Risk-off flows into defensive healthcare and home staples can provide relative outperformance during periods of market volatility.

Risks

  • Reimbursement and Medicare policy changes: Any adverse hospice reimbursement adjustments or Medicare Advantage structural shifts could compress hospice margins or reduce utilization.
  • Labor and wage pressure: Caregiver wage inflation, staffing shortages or higher benefits costs could materially increase operating expenses for VITAS and field technicians for Roto-Rooter.
  • Regulatory and compliance risk: Hospice and home-healthcare operations face licensing, inspection and documentation requirements that can trigger fines or operational constraints.
  • Cyclicality in home services: Economic weakness or a slowdown in housing activity could reduce Roto-Rooter revenue growth or push pricing pressure.
  • Valuation sensitivity to rates and multiples: Elevated absolute share price and multiple compression in a higher-rate environment could lead to meaningful downside absent growth clarity.
  • Execution and integration risk from acquisitions: Failure to integrate tuck-in deals or execute on expansion initiatives could limit growth and return expectations.

See today's live rating, score and targets

Members see the live hourly rating for CHE — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.